Clinical Trial Update: A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. [Phase 1]

View source ↗

Summary

A Phase 1/2, open-label dose-escalation study of elotuzumab in combination with bortezomib for multiple myeloma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elotuzumab (elotuzumab)
• Velcade (bortezomib)

Snippet

Sponsor: Abbott | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED